Purpose of Review The aim of this study is to discuss the background of PARP inhibitors and to provide an overview of the utility of these drugs for treatment of epithelial ovarian cancer. Recent Findings Numerous phase I–III trials are presented within the manuscript that outline the safety and efficacy of several PARP inhibitors in women with primary and recurrent ovarian cancer. There are now three FDA-approved PARP inhibitors for use in ovarian cancer patients in the USA: olaparib, niraparib, and rucaparib. These drugs have activity both alone and in combination with other agents, including chemotherapy and targeted anti-cancer drugs. Although PARP inhibitor toxicities often overlap with chemotherapy including myelosuppression, fatigue, and gastrointestinal distress, there are idiosyncratic differences in adverse event profiles and peculiar aspects of each drug. Additionally, the indications for use differ with respect to line of chemotherapy, whether a germline or somatic BRCA mutation is required, and maintenance versus active treatment intention. Although these were initially thought to be only applicable to patients with germline BRCA mutations, we now know that other patients benefit from these agents alone and in combination. Summary The first PARP inhibitor was approved for use in the USA less than 3
Current Obstetrics and Gynecology Reports – Springer Journals
Published: Mar 3, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera